Strategizing pressure for phase 3 trial on pritelivir for the immunocompetent
The FDA finally approved use of pritelivir for immunocompromised carriers. We need to figure out how to pressure Asahi Kasei, AiCuris, and VIDS Research to complete the phase 3 trial including immunocompetent carriers that they canceled. I refuse to sit and wait until the next HPIs hit the market, which won't be until approximately 2029 or likely later, or for them to twiddle their thumbs until they find it's pleasing to them to expand their customer base.
What can we do? Mass email all three of them? Emphasize that they are foregoing profits that could be made from maximizing sales volume? There is momentum with this approval, I want to strategize how best to make use of it.
Thank you everyone, and hope you are doing okay.